Clinical Trial Search

Primary: Dyadic Parent-Child Interaction Coding System (DPICS) - Behavior Counts — 67.2; 42.1; 53.8; 40.1 behaviors

Primary: Safety and Tolerability of the Oral RotaTeq® Vaccine — 18; 3 Individual Adverse Events

Primary: Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes — 4.4; 4.5; -3.4; -3.2 Incontinence Episodes

Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 10800; 13800; 16100; 19000 nmol*h/L

Primary: Intraocular Pressure (IOP) at Baseline — 21.23; 21.38 Millimeters of Mercury (mmHg)

Primary: Patient Response to Treatment for Primary Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 3.8; 3.6; 1.2…

Primary: Number of Patients With Adverse Events (AEs) and Serious Adverse Drug Reactions (SADRs) — 0; 6; 5; 0 participants

Primary: Participants With Any Event From the Composite of Cardiovascular Death (CV Death), Non-fatal Myocardial Infarction (MI), or Non-fatal Ischaemic Stroke — 613; 609…

Primary: Intraocular Pressure (IOP) at Baseline — 20.51; 20.65 Millimeters of Mercury (mmHg)

Primary: Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 2.4 units on a scale

Primary: Pharmacodynamics - Prothrombin Time (PT), Baseline Value — 15.8 Seconds

Primary: MicroMRI-derived Structural (Bone Volume Fraction-BVF) of the Distal Tibia at Baseline and After One and Two Years of Treatment. — 0.112; 0.104; 0.119; 0.111 unitless

Primary: Proportion of Index Subjects Free of Any Lice 14 Days After Their Last Treatment in the Modified ITT (LOCF) — 86.67; 45.33 percentage of subjects — p=<0.0001

Primary: Change From Month 6 to Month 12 in Disease Activity Sscore 28 (DAS28) — -0.39; 0.02 scores on a scale

Primary: % Change of Hippocampus Volume — -7.63; -7.28 percentage of change